AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9096188
Drug: Flucloxacillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flucloxacillin (1 g every 6 h i.v./p.o.)
Trial: 8212206
Drug: EC solution
RxNorm normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC solution
Trial: 30260145
Drug: Stem cells
RxNorm normalized name: Stem cells, apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stem cells therapy in addition to surgical left ventricular restoration (SVR)
Trial: 9041468
Drug: Intramuscular interferon-beta
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon-beta (IFN-beta) at a dosage of 6 million units three times per week for 6 months
Trial: 9041468
Drug: Intramuscular interferon-beta
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon-beta (IFN-beta)
Trial: 7701045
Drug: Ipsapirone 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipsapirone 10 mg
Trial: 26174461
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg daily, increased to 100 mg after 1 week)
Trial: 18286296
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB), 1.25 mg, 5‐7 days before PPV
Trial: 16448519
Drug: Metformin-glibenclamide 500/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin-glibenclamide 500/2.5 mg tablets (initial daily dose 1000/5 mg)
Trial: 16448519
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg plus rosiglitazone 4 mg (initial daily dose 1000-2000 mg + 4 mg)
Trial: 16448519
Drug: Metformin-glibenclamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin-glibenclamide
Trial: 2667746
Drug: Adjuvant progestagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant progestagen therapy (progesterone)
Trial: 17476008
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no additional therapy)
Trial: 1069314
Drug: 250 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mcg/kg N,N-Dimethyltryptamine (DMT) i.m.
Trial: 31121324
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg every 2 weeks) until progression, unacceptable toxicity, or consent withdrawal
Trial: 26041274
Drug: Immediate injection
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate injection of botulinum toxin type A (group A)
Trial: 26041274
Drug: 1-month delayed
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-month delayed injection of botulinum toxin type A (group B)
Trial: 25099322
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia with propofol-remifentanil
Trial: 22230384
Drug: Enalapril-FA tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril-FA tablet (10:0.4 mg, low FA group)
Trial: 22230384
Drug: Enalapril-FA tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril-FA tablet (10:0.8 mg, high FA group)
Trial: 22085872
Drug: Enalapril only
RxNorm normalized name: Enalapril only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril only (10 mg, control group)
Trial: 16192600
Drug: YES-ASP (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YES-ASP (20 weekly doses of high-dose L-asparaginase at 25,000 IU/m2)
Trial: 16192600
Drug: NO-ASP (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO-ASP (no high-dose L-asparaginase)
Trial: 9806581
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of chlamydial RNA molecules
Trial: 8961907
Drug: Sulfasalazine (SSZ)
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (SSZ) at a dosage of 2,000 mg/day
Trial: 3100007
Drug: Diltiazem 240
RxNorm normalized name: diltiazem 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 240 mg
Trial: 7295884
Drug: Sustained-release isosorbide
RxNorm normalized name: isosorbide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release isosorbide dinitrate (30 mg) in combination with standard-release pindolol (7.5 mg)
Trial: 7295884
Drug: Standard-release isosorbide
RxNorm normalized name: isosorbide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-release isosorbide dinitrate alone (30 mg)
Trial: 7295884
Drug: Standard-release pindolol
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-release pindolol alone (7.5 mg)
Trial: 7295884
Drug: Sustained-release pindolol
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release pindolol (7.5 mg) in combination with isosorbide dinitrate
Trial: 28116754
Drug: Esoxx (hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esoxx (hyaluronic acid-chondroitin sulphate based bioadhesive formulation) plus standard dose PPIs
Trial: 28116754
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus standard dose PPIs
Trial: 28116754
Drug: Esoxx plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esoxx plus standard dose PPIs
Trial: 21811062
Drug: Dried California
RxNorm normalized name: peptone,dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried California Mission figs (120 g/day) added to usual diet for 5 weeks
Trial: 19455481
Drug: Recovery beverage
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recovery beverage (40 g CHO + 20 g PRO)
Trial: 15549278
Drug: SSRI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI treatment (paroxetine or citalopram) for 4 weeks
Trial: 6497566
Drug: Haloperidol (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (fixed doses)
Trial: 20442660
Drug: Thiopental 5
RxNorm normalized name: thiopental 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 5 mg kg(‐1)
Trial: 20442660
Drug: Remifentanil doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil doses (3, 4, 5, or 6 microg kg(‐1))
Trial: 15472910
Drug: Oral Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Etoposide
Trial: 15472910
Drug: 3-drug combination
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-drug combination (actinomycin-D, vincristine, bleomycin)
Trial: 2007841
Drug: Felodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (5 mg b.i.d. for 2 weeks followed by 10 mg b.i.d. for a further 2 weeks)
Trial: 6442151
Drug: Ciprofloxacin 250
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 250 mg or 500 mg, 12-hourly for 10 days
Trial: 29366703
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of bivalent HPV vaccine
Trial: 26084406
Drug: Meropenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (1 g/8 hours) plus Daptomycin (6 mg/kg/day)
Trial: 26084406
Drug: Ceftazidime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2 g/8 hours)
Trial: 23727737
Drug: Control (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.04 ml distilled water)
Trial: 21995695
Drug: Doxazosin gastrointestinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin gastrointestinal therapeutic system (GITS) 4 mg
Trial: 8788832
Drug: Discarding 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discarding 1.5 ml of blood from the catheter
Trial: 6131635
Drug: Almitrine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine (0.5 mg/kg/h for 2 h)
Trial: 16344401
Drug: PV isolation
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PV isolation in combination with linear ablation joining the 2 superior PVs (roofline)
Trial: 7879931
Drug: Intraperitoneal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal morphine (1 mg in 20 ml saline)
Trial: 7879931
Drug: Intraperitoneal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal saline and 1 mg intravenous morphine
Trial: 7879931
Drug: Intraperitoneal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal bupivacaine (20 ml 0.25%)
Trial: 7879931
Drug: Interpleural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpleural morphine (1.5 mg in 30 ml saline)
Trial: 7879931
Drug: Interpleural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpleural saline and 1.5 mg intravenous morphine
Trial: 7879931
Drug: Interpleural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpleural bupivacaine (30 ml 0.25%)
Trial: 30657891
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rosuvastatin with candesartan/HCT
Trial: 19207601
Drug: Etravirine 800
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Etravirine 800 mg bid (Study 1)
Trial: 19207601
Drug: Etravirine 200
RxNorm normalized name: etravirine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etravirine 200 mg bid (Study 2)
Trial: 17227264
Drug: Heparin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (500 IU) in normal saline (HS)
Trial: 10745070
Drug: Lunelle Monthly
RxNorm normalized name: Lunelle Monthly Contraceptive 5mg-25mg/0.5ml Suspension for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lunelle Monthly Contraceptive Injection (MPA/E(2)C)
Trial: 9193192
Drug: Intravenous meta-chlorophenylpiperazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous meta-chlorophenylpiperazine (mCPP) 0.1 mg/kg
Trial: 8262115
Drug: Luteinizing hormone-releasing
RxNorm normalized name: (6-D-Tryptophan)luteinizing hormone-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone-releasing hormone analogue depot preparation and flutamide
Trial: 3543785
Drug: Balanced Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced Saline Solution (BSS)
Trial: 22744718
Drug: Short- and
RxNorm normalized name: ALLERGENIC EXTRACT,RAGWEED,SHORT AND TALL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short- and long-term antibiotic treatments
Trial: 18986066
Drug: Facial biological
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facial biological motion recognition task
Trial: 11488118
Drug: Standard polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard polyethylene glycol preparation
Trial: 9232521
Drug: RheothRx injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RheothRx injection (poloxamer 188) administered as an intravenous infusion at doses of 10, 30, and 45 mg/kg/h for 72 h, 60 mg/kg/h for 43.3 to 72 h, 60 and 90 mg/kg/h for 24 h
Trial: 8121319
Drug: Buflomedil (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buflomedil (600 mg per day for 21 days)
Trial: 27267983
Drug: Multimodal educational
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal educational intervention consisting of two online modules, a face-to-face workshop for GP trainees, a face-to-face workshop for their supervisors, and case-based discussions in weekly meetings.
Trial: 19644849
Drug: Golimumab 50
RxNorm normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab 50 mg plus MTX
Trial: 18383539
Drug: Golimumab 100
RxNorm normalized name: golimumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab 100 mg every 2 weeks plus MTX
Trial: 12580985
Drug: High enalaprilat
RxNorm normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High enalaprilat concentration (above 50 ng ml(‐1), n = 17)
Trial: 12580985
Drug: Low enalaprilat
RxNorm normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low enalaprilat concentration (below 10 ng ml(‐1), n = 18)
Trial: 11966062
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral prednisolone (30 mg if age < 5 years; 60 mg if age > 5 years)
Trial: 2983641
Drug: Oral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estrogen treatment
Trial: 29045621
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of proton pump inhibitors (PPIs)
Trial: 29045621
Drug: Cumulative dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative dosage of PPIs use (per microgram)
Trial: 26175036
Drug: Fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2 laser, NB‐UVB phototherapy, and 0.05% clobetasol propionate cream (Group A)
Trial: 26175036
Drug: NB‐UVB phototherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NB‐UVB phototherapy and 0.05% clobetasol propionate cream (Group B)
Trial: 21187536
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) - 10 mg per kg body weight, administered intravenously 10 minutes prior to incision
Trial: 17982182
Drug: Prasugrel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (60 mg loading dose and 10 mg daily maintenance dose)
Trial: 17982182
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose and 75 mg daily maintenance dose)
Trial: 15476575
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and cholecalciferol supplement (500 mg of elemental calcium and 400 IU cholecalciferol)
Trial: 15476575
Drug: Neridronate (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neridronate (25 mg intramuscularly every month) in addition to calcium and cholecalciferol supplement
Trial: 11825486
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) with total parenteral nutrition (TPN) for 7 days
Trial: 11825486
Drug: total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: total parenteral nutrition (TPN) only for 7 days
Trial: 8164328
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) continuous infusion at a rate of 50 ng.kg‐1 x min‐1
Trial: 8164328
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) continuous infusion
Trial: 2450113
Drug: Topical flunisolide
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical flunisolide (50 micrograms, each nostril, twice daily) for 1 week before antigen challenge
Trial: 26857054
Drug: Internet-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive-behavioral therapy for insomnia (CBT-I)
Trial: 22774774
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (dutasteride + tamsulosin)
Trial: 17935974
Drug: Rituximab (Rit)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (Rit) as a single agent
Trial: 17935974
Drug: Rituximab (Rit)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (Rit) in combination with chemotherapy
Trial: 17935974
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of Rituximab to standard chemotherapy
Trial: 14660152
Drug: Methamphetamine users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methamphetamine users entering treatment for methamphetamine dependence
Trial: 15471834
Drug: L‐dopa therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐dopa therapy response (normal scan)
Trial: 15471834
Drug: L‐dopa therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐dopa therapy response (abnormal scan)
Trial: 2105052
Drug: Cyclic total
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic total parenteral nutrition (15 h/d)
Trial: 2105052
Drug: Continuous total
RxNorm normalized name: Zinc Oxide 7.25 g in 100 g / Titanium Dioxide 3.5 g in 100 g TOPICAL SPRAY [Kids SPF50 Plus Mineral Sunscreen Continuous Totally Tropical]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous total parenteral nutrition (24 h/d)
Trial: 31652407
Drug: Greek yogurt
RxNorm normalized name: Greek pitch
DrugBank: Rosin (DB11165)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greek yogurt (GY) (20 g protein, 208 mg calcium/dose)
Trial: 31652407
Drug: Placebo pudding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pudding (PP) (0 g protein, 0 g calcium/dose)
Trial: 15476449
Drug: Diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet plus folic acid (5 mg/day) plus vitamin B12 (500 microg/day) for 1 month
Trial: 9771301
Drug: Target-controlled alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target-controlled alfentanil infusion
Trial: 3397586
Drug: 4‐methylpyrazole in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐methylpyrazole in hydrophilic ointment
Trial: 3397586
Drug: Hydrophilic ointment
RxNorm normalized name: HYDROPHILIC OINTMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrophilic ointment alone
Trial: 31730565
Drug: CHO +
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO + KME (573 mg·kg of a ketone monoester supplement)
Trial: 31730565
Drug: CHO +
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO + PLA (8% carbohydrate-electrolyte solution)
Trial: 26132839
Drug: Chikungunya virus
RxNorm normalized name: Chikungunya virus Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chikungunya virus (CHIKV) IgG antibodies testing
Trial: 21666979
Drug: Placebo (inert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inert compound)
Trial: 19709989
Drug: Negative credibility
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative credibility cues (adverts, pharmaceutical sponsorship, donation button)
Trial: 15121070
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (controls, 33 patients)
Trial: 11476360
Drug: Lispro insulin
RxNorm normalized name: Lispro insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lispro insulin (LP)
Trial: 9614617
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin (ACT)
Trial: 31181017
Drug: Domperidone 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 0.25 mg/kg with oral rehydration therapy (ORT)
Trial: 31181017
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with oral rehydration therapy (ORT)
Trial: 24653477
Drug: Dignity therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dignity therapy plus standard care
Trial: 15283941
Drug: Oral hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hormone replacement therapy (estradiol 2 mg/norethisterone acetate 1 mg-Kliogest)
Trial: 8313746
Drug: Nylestriol 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nylestriol 2 mg/2 weeks (Group A)
Trial: 8313746
Drug: Nylestriol 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nylestriol 1 mg/2 weeks (Group B)
Trial: 29031768
Drug: Hyperbaric oxygenation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygenation therapy (100% oxygen in hyperbaric conditions)
Trial: 11824669
Drug: Atorvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (40 mg the evening before and 40 mg the morning of surgery)
Trial: 9572206
Drug: Telephone calls
RxNorm normalized name: Mosco Corn & Callus Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone calls from registered nurses, one or two times weekly from 24 weeks' through 37 weeks' gestation
Trial: 9572206
Drug: Telephone calls
RxNorm normalized name: Mosco Corn & Callus Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone calls from registered nurses, one or two times weekly from 24 weeks' through 37 weeks' gestation in low-income black women 19 years of age and older